Navigation Links
Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
Date:10/27/2008

WTA2 Kits Offer Rapid, Robust Amplification of Partially Degraded RNA

ST. LOUIS, Oct. 28 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the launch of its TransPlex(R) Whole Transcriptome Amplification (WTA2) technology (http://www.sigma.com/wta). TransPlex technology is believed to be the fastest, most sensitive and robust method available for amplifying total RNA from a variety of sample tissue sources such as animals, plants, and microorganisms. Optimized for formalin-fixed and paraffin-embedded tissue samples, WTA2 is the second addition to the patent-pending suite of WTA products designed to study RNA in vitro.

"Sigma-Aldrich is committed to bringing best-in-class technologies to the genomic research community," said Helge Bastian, Vice President of Marketing for Sigma-Aldrich's Research Biotech Business Unit. "The TransPlex(R) Whole Transcriptome Amplification product line adds an important tool for researchers who work with limited quantity and quality of RNA samples."

The TransPlex WTA technology creates a cDNA library from total RNA template and then amplifies the cDNA library in a single PCR reaction. The TransPlex reagents and protocols, optimized to ensure clonal and stochastic amplification of all expressed genes and exons, allow RNA samples to be amplified 1,000-10,000 fold in less than four hours. Sigma-Aldrich's WTA2 technology is highly robust, designed for use with RNA is partially degraded, as in formalin-fixed paraffin-embedded tissue derived from tumor samples.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.

About Rubicon Genomics: Rubicon, located in Ann Arbor, MI, commercializes its OmniPlex(R) and EnzyPlex(R) families of technologies for diagnostics, research, and service. Rubicon has partnered with large diagnostic and pharmaceutical companies to develop proprietary MethylPlex(R) diagnostic and predictive tests for methylated DNA biomarkers discovered for prostate, bladder, breast, and lung cancer. Rubicon will continue to offer commercial services for whole genome and whole transcriptome amplification from DNA, serum, and formalin-fixed sections. OmniPlex(R), EnzyPlex(R), GenomePlex(R), MethylPlex(R), and TransPlex(R) are trademarks of Rubicon Genomics. More information can be found at http://www.rubicongenomics.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 For today, Stock-Callers.com ... novel drug development and clinical research aimed at treating diseases ... (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. ... ). You can access our complimentary research reports on these ... ...
(Date:4/19/2017)... (PRWEB) , ... April 19, 2017 , ... Nobilis ... Disorder , Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress ... registration of an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based ...
(Date:4/19/2017)... Calif. , April 19, 2017  As ... Drug Abuse and Heroin Summit ,  Proove┬« Biosciences, ... study analyzing genetics, environmental, and lifestyle factors to ... from the University of Southern California (USC), the ... , and Proove publish results showing that Proove ...
(Date:4/18/2017)... ... 18, 2017 , ... CallTower, an industry-leading unified ... Provider. , Channel Partners program recognizes IT and telecom channel leaders who help ... of the channel during transition and convergence. CallTower is the first provider to ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):